Gland Pharma Secures FDA Approval for Vitamin K Injectable Amid Profit Decline

Show Full Summary
- Gland Pharma Ltd received FDA approval for phytonadione injectable emulsion.
- The product is bioequivalent to Hospira, Inc.'s vitamin K1 injectable.
- Gland Pharma's net profit declined 15.7% to ₹163.5 crore.
- Revenue increased 2.4% to ₹1,405.8 crore year-on-year.
The sources of this summary are listed below. Click to view.